Drug Search Results
More Filters [+]

Rimacalib

Alternative Names: rimacalib, smp-114, smp 114, smp114
Latest Update: 2009-03-13
Latest Update Note: Clinical Trial Update

Product Description

Rimacalib (SMP 114) is a Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor, with IC50s of ~1 ?M for CaMKII? to ~30 ?M for CaMKII?.

Mechanisms of Action: CAMK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sumitomo Dainippon Pharma Co
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rimacalib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ASPECTS- Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment with SMP-114

P2

Terminated

Arthritis, Rheumatoid

2007-11-26

D2450174

P2

Terminated

Arthritis, Rheumatoid

None

Recent News Events

Date

Type

Title